Immune response to ART initiation in advanced HIV infection

OBJECTIVES Our objective was to compare the immunological responses to commonly used antiretroviral therapy (ART) regimens among people with advanced HIV in the USA and to assess virological outcomes and regimen persistence. METHODS This study included ART-naïve adults with advanced HIV infection (CD4 cell count <200 cells/μL) initiating ART with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), boosted darunavir (bDRV), dolutegravir (DTG), or elvitegravir (EVG/c)-containing regimens between 1 January 2018 and 31 December 2020 in the Observational Pharmaco-Epidemiology Research and Analysis (OPERA) cohort. Cox proportional hazards models and linear mixed models with random intercept were fit with inverse probability of treatment weighting. RESULTS Overall, 1349 people with advanced HIV (816 B/F/TAF, 253 DTG, 146 EVG/c, 134 bDRV) were followed for a median of 22 months. Compared with B/F/TAF, a lower likelihood of achieving a CD4 cell count ≥200 cells/μL was observed with bDRV (hazard ratio [HR] 0.76; 95% confidence interval [CI] 0.60-0.96), DTG (HR 0.82; 95% CI 0.69-0.98), and EVG/c (HR 0.73; 95% CI 0.57-0.93). All groups had a similar pattern of CD4:CD8 ratio changes: a rapid increase in the first 6 months (ranging from +0.15 to +0.16 units), followed by a slower increase thereafter. Only 40 individuals (4%) achieved CD4:CD8 ratio normalization (≥1). B/F/TAF was associated with a faster time to virological suppression (viral load <200 copies/mL) and a slower time to discontinuation compared with other regimens. CONCLUSIONS Among people with advanced HIV infection, B/F/TAF initiation was associated with faster CD4 cell count recovery and favourable virological outcomes compared with bDRV-, DTG-, and EVG/c-based regimens, although no difference was observed in CD4:CD8 ratio changes over time across regimens.

[1]  J. Miro,et al.  Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study , 2022, EClinicalMedicine.

[2]  V. Vannappagari,et al.  886. The Impact of the COVID-19 Pandemic on Clinical Follow-Up, Monitoring and Regimen Discontinuation for People Living with HIV in the US , 2021, Open Forum Infectious Diseases.

[3]  P. Chan,et al.  Characterizing the Impact of COVID-19 on Pre-Exposure Prophylaxis (PrEP) Care , 2021, AIDS and Behavior.

[4]  E. Herrmann,et al.  Reasons for Choice of Antiretroviral Regimens in HIV Patients Presenting Late for Initial Treatment in Europe. , 2021, AIDS Patients Care and STDs.

[5]  B. Hill,et al.  COVID-19 Pandemic, Pre-exposure Prophylaxis (PrEP) Care, and HIV/STI Testing Among Patients Receiving Care in Three HIV Epidemic Priority States , 2021, AIDS and Behavior.

[6]  S. Reus,et al.  Impact of Advanced HIV Disease on Quality of Life and Mortality in the Era of Combined Antiretroviral Treatment , 2021, Journal of clinical medicine.

[7]  Helena Díaz Cuervo,et al.  1036. Persistence of Guideline-Recommended Antiretroviral Therapy Regimens among Persons Living with HIV Newly Initiating Treatment in the US , 2020 .

[8]  Don E. Smith,et al.  Trends in practice: attitudes and challenges in the diagnosis, treatment and management of HIV infection in Australia , 2020, Internal medicine journal (Print).

[9]  C. Sabin,et al.  Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors , 2020, HIV medicine.

[10]  G. d’Ettorre,et al.  A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) , 2019, PloS one.

[11]  W. Armstrong,et al.  Management of Advanced Human Immunodeficiency Virus Disease. , 2019, Infectious Disease Clinics of North America.

[12]  Richard D Moore,et al.  Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  R. Striker,et al.  Imbalance in the game of T cells: What can the CD4/CD8 T-cell ratio tell us about HIV and health? , 2017, PLoS pathogens.

[14]  Michael Friend,et al.  Monitoring selected national HIV prevention and care objectives by using HIV surveillance data : United States and 6 dependent areas, 2015 , 2017 .

[15]  G. Angarano,et al.  The Revival of an "Old" Marker: CD4/CD8 Ratio. , 2017, AIDS reviews.

[16]  V. Calvez,et al.  Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Lederman,et al.  HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality , 2014, PLoS pathogens.

[18]  M. Friend,et al.  Diagnoses of HIV infection in the United States and dependent areas, 2016 , 2013 .

[19]  M. Gill,et al.  The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year Period , 2011, AIDS research and treatment.

[20]  A. Mocroft,et al.  Late presentation of HIV infection: a consensus definition , 2011, HIV medicine.

[21]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[22]  K. Ruxrungtham,et al.  Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis , 2009, AIDS.

[23]  Stephen R Cole,et al.  Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.

[24]  M. Battegay,et al.  Antiretroviral therapy of late presenters with advanced HIV disease. , 2008, The Journal of antimicrobial chemotherapy.

[25]  C. Sabin,et al.  Late Diagnosis of HIV Infection: Epidemiological Features, Consequences and Strategies to Encourage Earlier Testing , 2007, Journal of acquired immune deficiency syndromes.

[26]  M. Gill,et al.  The high cost of medical care for patients who present late (CD4<200 cells/μL) with HIV infection , 2004, HIV medicine.